US 11820781
Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
granted A61KA61K31/497A61K31/5377
Quick answer
US patent 11820781 (Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway) held by NURIX THERAPEUTICS, INC. expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NURIX THERAPEUTICS, INC.
- Grant date
- Tue Nov 21 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 34
- CPC classes
- A61K, A61K31/497, A61K31/5377, A61P, A61P35/00